67 results about "Pandrug resistant bacteria" patented technology

The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).

This invention relates to beta-lactam compounds in combination with further drugs, e.g. beta-lactamase inhibitors (BLIs), for use in the treatment and prophylaxis of infections caused by resistant bacteria.

A high-expression, high-purity and high-activity gene-recombinant human lysozyme, its preparing process and the medical composition of antibiotic and the said human lysozyme for treating bacterial and fungus infection, drug-resistant bacteria infection, and the sequela caused by gram-negative bacteria infection are disclosed.

The present invention is to provide an agent for preventing and treating drug-resistant bacterial infection for livestock / fowls or fish and shellfish, using particular microbial agents as active components, without using synthetic antibacterial substances or antibiotics, and a method for preventing and treating its infection. By using lactic acid bacteria, their dead bacteria or treated substances thereof, or Mygasphaera elsdenii as active components, for an agent for preventing and treating drug-resistant bacterial infection for livestock / fowls or fish and shellfish carrying or being infected by drug-resistant bacteria such as Vancomycin, particularly by using Enterococcus faecalis, Enterococcus faecium as lactic acid bacteria, the above mentioned object was resolved.

The invention provides a novel composition useful in the treatment of resistant bacterial infections, said composition comprising an extract obtained from Azadiracta indica or Melia azadirachta and an effective amount of an antibiotic or chemotherapuetic antibacterial drug. Further, the invention provides a method for the treatment of resistant bacterial infections. The invention also provides a process for the preparation of the composition of the invention.

The invention provides application of polypeptide RK12 in preparation of a medicine for treating acne. The new application of the polypeptide RK12 is used for preparing the medicine for treating the acne, the polypeptide RK12 has a remarkable inhibition effect on propionibacterium acnes and clindamycin-resistant propionibacterium acnes, and compared with antibiotics, the polypeptide RK12 is low in drug resistance, has concentration and time dependence, and has a good application prospect in preparation of medicines for treating the acne and the clindamycin-resistant propionibacterium acnes. The research result of an in-vitro antibacterial spectrum experiment also proves that the composition can rapidly inhibit the growth of propionibacterium acnes and clindamycin-resistant propionibacterium acnes, the research result of an in-vitro anti-inflammatory experiment also proves that the composition has an obvious anti-inflammatory effect, and the composition is not easy to generate drug-resistant bacteria due to an antibacterial mechanism different from that of antibiotics. According to the new strategy and thought for treating acne provided by the invention, the antibacterial action mechanism is helpful for clinically limiting the influence of antibiotic resistance.

The present invention is to provide an agent for preventing and treating drug-resistant bacterial infection for livestock / fowls or fish and shellfish, using particular microbial agents as active components, without using synthetic antibacterial substances or antibiotics, and a method for preventing and treating its infection. By using lactic acid bacteria, their dead bacteria or treated substances thereof, or Mygasphaera elsdenii as active components, for an agent for preventing and treating drug-resistant bacterial infection for livestock / fowls or fish and shellfish carrying or being infected by drug-resistant bacteria such as Vancomycin, particularly by using Enterococcus faecalis, Enterococcus faecium as lactic acid bacteria, the above mentioned object was resolved.

A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant Pseudomonas aeruginosa, including nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. The current invention relates to mitigation of drug resistant bacteria, for example in hospitals and in food animals, and to the identification. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The invention also relates to the treatment of multi-drug resistant biofilms which mimic in vivo conditions. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRF and alternative resistant strain-induced illnesses without compromising the balance of the beneficial flora in the physiological and ecological microenvironments. The combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in treating multi-drug resistant pathogens.

The invention discloses an antibacterial peptide Scybaumancin105-127 and application thereof, the antibacterial peptide is found in Scylla paramamosain for the first time, the molecular formula of the antibacterial peptide is C106H188N36O28S3, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The antibacterial peptide Scybaumancin105-127 disclosed by the invention has good antibacterial activity on acinetobacter baumannii, shigella flexneri, escherichia coli, pseudomonas aeruginosa, cryptococcus neoformans, listeria monocytogenes, enterococcus faecium and propionibacterium acnes, and has no cytotoxicity on normal cells. The antibacterial peptide Scybaumancin105-127 has high antibacterial activity, safety and non-toxic, also has relatively strong antibacterial activity on clinical drug-resistant bacteria, and has a wide application prospect.

The invention discloses a group of glycopeptides compounds with anti-resistance bacterial activity. The glycopeptides compounds in accordance with a general formula (I) are as shown in the following specification. The invention further provides a preparation method and an application for the above glycopeptides compounds. Through testing, compared with a second-generation glycopeptides pharmaceutical oritavancin, the glycopeptides antibiotic compounds have the higher inhibitory activity to endurance strains, especially MRSA or VRE. Through further testing, the most of the glycopeptides compounds have the higher safety than the oritavancin, and can be used for preparing pharmaceuticals for treating or preventing various diseases, such as skin and soft tissue infection, cephalomeningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema, caused by bacterial infection.

A high-expression, high-purity and high-activity gene-recombinant human lysozyme, its preparing process and the medical composition of antibiotic and the said human lysozyme for treating bacterial and fungus infection, drug-resistant bacteria infection, and the sequela caused by gram-negative bacteria infection are disclosed.

The invention relates to the field of biomedicine and in particular relates to an antibacterial polypeptide. Part of active amino acids of the antibacterial polypeptide of Cathelicidin family is mutated based on the antibacterial polypeptide of Cathelicidin family, and then the antibacterial polypeptide with high inhibitory activity to penicilin-resistant bacterium is obtained by solid phase chemical synthesis. The result of pharmacodynamic tests shows that the antibacterial polypeptide provided by the invention has good in vitro antibacterial activity and is applicable to treating diseases about drug-resistant bacterial infection.

The present invention relates a hexane bioactive fraction and obtained from the roots of an aromatic plant named Vetiveria zizanioides commonly found in India for inhibiting the growth of drug resistant bacterial infections in humans and animals; also relates to a pharmaceutical composition comprising the bioactive extract with other additives for inhibiting the growth of drug resistant bacterial infections in humans and animals and a process for the isolation of said bioactive extract